NGEN (NervGen Pharma) Total Liabilities: $0.00 Mil (As of Mar. 2026)


NGEN NervGen Pharma Corp NGEN
22 GF Score
Price $1.87
! 2 Warning Signs
View Full Analysis

What is NervGen Pharma Total Liabilities?

NervGen Pharma NGEN -1.06% 22 Total Liabilities is $0.00 Mil as of Mar. 2026. GuruFocus rates NGEN with a GF Score™ of 22/100. The stock has 2 warning signs investors should review.

NervGen Pharma's Total Liabilities for the quarter that ended in Mar. 2026 was $0.00 Mil.

NervGen Pharma's quarterly Total Liabilities increased from Sep. 2025 ($11.58 Mil) to Dec. 2025 ($14.30 Mil) but then declined from Dec. 2025 ($14.30 Mil) to Mar. 2026 ($0.00 Mil).

NervGen Pharma's annual Total Liabilities increased from Dec. 2023 ($11.36 Mil) to Dec. 2024 ($11.87 Mil) and increased from Dec. 2024 ($11.87 Mil) to Dec. 2025 ($14.30 Mil).

NervGen Pharma Total Liabilities Historical Data

* Premium members only.

The historical data trend for NervGen Pharma's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NervGen Pharma Total Liabilities Chart

NervGen Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only 0.84 7.67 11.36 11.87 14.30

NervGen Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.07 13.05 11.58 14.30 0.00
NGEN
22GF Score
NervGen Pharma Corp NGEN
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NervGen Pharma Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

NervGen Pharma's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=14.304+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=14.30

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=16.825-2.52
=14.31

NervGen Pharma's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=N/A

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=N/A-N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $0.00 Mil mean?
NervGen Pharma (NGEN) has a Total Liabilities of $0.00 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for NervGen Pharma and its competitors.
Is NervGen Pharma's Total Liabilities too high?
NervGen Pharma's current Total Liabilities is $0.00 Mil. Overall, NervGen Pharma has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does NervGen Pharma's Total Liabilities compare to CNTN and ELTX?
NervGen Pharma's Total Liabilities of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for NervGen Pharma and its competitors. NervGen Pharma's current Total Liabilities is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NervGen Pharma stock overvalued right now?
NervGen Pharma (NGEN) has a current Total Liabilities of $0.00 Mil. The current Total Liabilities is $0.00 Mil. NervGen Pharma's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For NervGen Pharma (NGEN), the current Total Liabilities is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NervGen Pharma Business Description

Other Exchanges 9UA:Germany
Address 112-970 Burrard Street, Unit 1290, Vancouver, BC, CAN, V6Z 2R4
NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.
22GF Score

Get the complete analysis for NGEN

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.87
Price